Broad consideration of socio-economic factors when setting prices for a first-line heart disease medicine in multiple priority countries*

AstraZeneca considers five socio-economic factors when setting prices for a first-line heart disease medicine and targets 27% of priority countries. This is comparatively broad as the industry considers only two socio-economic factors per strategy, on average.

Summary  

  • What: AstraZeneca’s intra-country equitable pricing strategy for ticagrelor (Brilinta®) considers five socio-economic factors and targets 27% of priority countries relevant for this product.
  • Objective: The strategy aims to ensure affordability of this product in India, China and Brazil.
  • Details: This relates to AstraZeneca’s heart disease product, ticagrelor (Brilinta®), in Brazil, China and India.
  • Socio-economic factors considered: (1) disease burden, (2) the availability of public financing, (3) levels of inequality, (4) supply chain conditions and (5) patient awareness.

Looking closer

AstraZeneca’s intra-country equitable pricing strategy for ticagrelor (Brilinta®) considers five socio-economic factors: disease burden, the availability of public financing, levels of inequality, supply chain conditions and patient awareness. The strategy targets 27% of priority countries relevant for this product, namely, Brazil, China and India and it targets population segments within these countries. This strategy is particularly important as ticagrelor is used first- line in the prevention of atherothrombotic events. It is also on patent, and AstraZeneca is the only manufacturer.

Sign up to receive updates about our work.